255 related articles for article (PubMed ID: 28439919)
21. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
Nardin C; Borot S; Beaudoin MA; Cattin F; Puzenat E; Gauthier AS; Schillo F; Borg C; Aubin F
Invest New Drugs; 2019 Apr; 37(2):375-377. PubMed ID: 30145624
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.
Salomon G; Maza A; Boulinguez S; Paul C; Lamant L; Tournier E; Mazereeuw-Hautier J; Meyer N
Br J Dermatol; 2018 May; 178(5):1199-1203. PubMed ID: 29274233
[TBL] [Abstract][Full Text] [Related]
23. A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
Ghosn J; Vicino A; Michielin O; Coukos G; Kuntzer T; Obeid M
J Immunother Cancer; 2018 Oct; 6(1):110. PubMed ID: 30348223
[TBL] [Abstract][Full Text] [Related]
24. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
Yatim N; Mateus C; Charles P
Rev Med Interne; 2018 Feb; 39(2):130-133. PubMed ID: 29277453
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
[TBL] [Abstract][Full Text] [Related]
26. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
[TBL] [Abstract][Full Text] [Related]
27. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
[TBL] [Abstract][Full Text] [Related]
28. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
29. [Two cases of granuloma annulare under anti-PD1 therapy].
Charollais R; Aubin F; Roche-Kubler B; Puzenat E
Ann Dermatol Venereol; 2018 Feb; 145(2):116-119. PubMed ID: 29221649
[TBL] [Abstract][Full Text] [Related]
30. Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.
Quach HT; Robbins CJ; Balko JM; Chiu CY; Miller S; Wilson MR; Nelson GE; Johnson DB
Oncologist; 2019 Jul; 24(7):872-876. PubMed ID: 30936376
[TBL] [Abstract][Full Text] [Related]
31. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
32. Pembrolizumab-Induced Pancytopenia: A Case Report.
Atwal D; Joshi KP; Ravilla R; Mahmoud F
Perm J; 2017; 21():17-004. PubMed ID: 28746020
[TBL] [Abstract][Full Text] [Related]
33. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
Arianayagam S; Ieremia E; Matin RN
Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
[No Abstract] [Full Text] [Related]
34. Hypophysitis secondary to pembrolizumab: a case report and review of the literature.
Montero Pérez O; Sánchez Escudero L; Guzmán Ramos MI; Aviñó Tarazona V
Anticancer Drugs; 2022 Jan; 33(1):94-99. PubMed ID: 34261922
[TBL] [Abstract][Full Text] [Related]
35. Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab.
Navarro-Perea C; Garcia-Gonzalez J; Perez-Blazquez E
Indian J Ophthalmol; 2019 Dec; 67(12):2075-2077. PubMed ID: 31755465
[TBL] [Abstract][Full Text] [Related]
36. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
Rofe O; Bar-Sela G; Keidar Z; Sezin T; Sadik CD; Bergman R
Clin Exp Dermatol; 2017 Apr; 42(3):309-312. PubMed ID: 28211077
[TBL] [Abstract][Full Text] [Related]
37. Polymyalgia rheumatica due to pembrolizumab therapy.
Iskandar A; Hwang A; Dasanu CA
J Oncol Pharm Pract; 2019 Jul; 25(5):1282-1284. PubMed ID: 30249155
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
40. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
